Literature DB >> 28490979

Dose to organ at risk and dose prescription in liver SBRT.

Rives Michel1, Izar Françoise1, Parent Laure1, Modesto Anouchka1, Portier Guillaume2, Kirzin Sylvain2.   

Abstract

Stereotactic body radiation therapy (SBRT) is delivered in a curative intent to many primary and secondary tumors. Concerning liver metastasis, SBRT can be safely delivered using one to five fractions. An excellent local control is obtained with doses from 20 to 60 Gy. For primary hepatic tumors, results are also good, but the risk of hepatic toxicity related to liver pre-existent pathology must be taken into account. Radiation induced liver disease (RILD) is not frequent in its classical presentation, but modifications of liver enzymes are often observed. Other toxicities of SBRT on the duodenum, small bowel and biliary tract are also described. With respect to contraindications and dose limitations on surrounding structures, SBRT is well tolerated and takes place among curative treatment of liver tumors, as surgery, radiofrequency and embolization.

Entities:  

Keywords:  Hepatocellular; Liver; Metastasis; Radiotherapy; Stereotactic; Toxicity

Year:  2017        PMID: 28490979      PMCID: PMC5411900          DOI: 10.1016/j.rpor.2017.03.001

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  45 in total

Review 1.  Improved radiotherapy for primary and secondary liver cancer: stereotactic body radiation therapy.

Authors:  Chad Tao; Li-Xi Yang
Journal:  Anticancer Res       Date:  2012-02       Impact factor: 2.480

2.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

3.  Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA.

Authors:  Naoko Sanuki; Atsuya Takeda; Yohei Oku; Takahisa Eriguchi; Shuichi Nishimura; Yosuke Aoki; Tomikazu Mizuno; Shogo Iwabuchi; Etsuo Kunieda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

4.  Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases.

Authors:  Alan W Katz; Madeleine Carey-Sampson; Ann G Muhs; Michael T Milano; Michael C Schell; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

5.  Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame.

Authors:  J Wulf; U Hädinger; U Oppitz; B Olshausen; M Flentje
Journal:  Radiother Oncol       Date:  2000-11       Impact factor: 6.280

Review 6.  Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice.

Authors:  Robert D Timmerman; Joseph Herman; L Chinsoo Cho
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

7.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases.

Authors:  Joern Wulf; Matthias Guckenberger; Ulrich Haedinger; Ulrich Oppitz; Gerd Mueller; Kurt Baier; Michael Flentje
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

Review 8.  Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities.

Authors:  Jonathan Klein; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-06       Impact factor: 7.038

9.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Regina V Tse; Maria Hawkins; Gina Lockwood; John J Kim; Bernard Cummings; Jennifer Knox; Morris Sherman; Laura A Dawson
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

View more
  7 in total

1.  Editorial.

Authors:  Miquel Macià; Carmen Llacer-Moscardo
Journal:  Rep Pract Oncol Radiother       Date:  2016-10-15

2.  Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.

Authors:  Anthony D Nehlsen; Kunal K Sindhu; Thomas Wolken; Fahad Khan; Christopher K Kyriakakos; Stephen C Ward; Erin Moshier; Bachir Taouli; Michael Buckstein
Journal:  Radiol Imaging Cancer       Date:  2022-07

3.  Repeated SBRT for in- and out-of-field recurrences in the liver.

Authors:  Eleni Gkika; Iosif Strouthos; Simon Kirste; Sonja Adebahr; Michael Schultheiss; Dominik Bettinger; Ralph Fritsch; Volker Brass; Lars Maruschke; Hannes Philipp Neeff; Sven Arke Lang; Ursula Nestle; Anca-Ligia Grosu; Thomas Baptist Brunner
Journal:  Strahlenther Onkol       Date:  2018-10-23       Impact factor: 3.621

4.  A phase I trial of Proton stereotactic body radiation therapy for liver metastases.

Authors:  Joseph I Kang; Daniel C Sufficool; Chung-Tsen Hsueh; Andrew J Wroe; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang
Journal:  J Gastrointest Oncol       Date:  2019-02

5.  Slice-stacking T2-weighted MRI for fast determination of internal target volume for liver tumor.

Authors:  Silu Han; Xiao Liang; Tian Li; Fang-Fang Yin; Jing Cai
Journal:  Quant Imaging Med Surg       Date:  2021-01

6.  Radiation-Induced Metabolic Shifts in the Hepatic Parenchyma: Findings from 18F-FDG PET Imaging and Tissue NMR Metabolomics in a Mouse Model for Hepatocellular Carcinoma.

Authors:  Yi-Hsiu Chung; Cheng-Kun Tsai; Ching-Fang Yu; Wan-Ling Wang; Chung-Lin Yang; Ji-Hong Hong; Tzu-Chen Yen; Fang-Hsin Chen; Gigin Lin
Journal:  Molecules       Date:  2021-04-28       Impact factor: 4.411

7.  Novel Clinically Weight-Optimized Dynamic Conformal Arcs (WO-DCA) for Liver SBRT: A Comparison with Volumetric Modulated Arc Therapy (VMAT).

Authors:  Yucel Saglam; Yasemin Bolukbasi; Ali Ihsan Atasoy; Fatih Karakose; Mustafa Budak; Vildan Alpan; Erkan Topkan; Ugur Selek
Journal:  Ther Clin Risk Manag       Date:  2021-09-28       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.